These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34287610)

  • 1. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    Rubin R
    JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
    [No Abstract]   [Full Text] [Related]  

  • 2. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 3. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 4. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 5. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 6. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 7. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
    Karlawish J; Grill JD
    Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
    [No Abstract]   [Full Text] [Related]  

  • 8. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Drug Approval and the Ethics of Desperation.
    Largent EA; Peterson A; Lynch HF
    JAMA Intern Med; 2021 Dec; 181(12):1555-1556. PubMed ID: 34694325
    [No Abstract]   [Full Text] [Related]  

  • 10. Solanezumab and the amyloid hypothesis for Alzheimer's disease.
    Le Couteur DG; Hunter S; Brayne C
    BMJ; 2016 Dec; 355():i6771. PubMed ID: 28034844
    [No Abstract]   [Full Text] [Related]  

  • 11. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab: look before leaping.
    Perlmutter JS
    Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
    [No Abstract]   [Full Text] [Related]  

  • 13. Doubts persist for claimed Alzheimer's drug.
    Servick K
    Science; 2019 Dec; 366(6471):1298. PubMed ID: 31831649
    [No Abstract]   [Full Text] [Related]  

  • 14. Why aducanumab is important.
    Cummings J
    Nat Med; 2021 Sep; 27(9):1498. PubMed ID: 34413516
    [No Abstract]   [Full Text] [Related]  

  • 15. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.
    Musiek ES; Gomez-Isla T; Holtzman DM
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651585
    [No Abstract]   [Full Text] [Related]  

  • 16. A carte blanche approval in Alzheimer's.
    Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
    [No Abstract]   [Full Text] [Related]  

  • 17. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    Woloshin S; Kesselheim AS
    JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
    [No Abstract]   [Full Text] [Related]  

  • 20. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.